Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sertraline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sertraline SCHEMBL29690831 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL3841967 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL29374222 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL14028076 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL7922153 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL3947169 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL30244837 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL3856872 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL137619 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL137618 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0028901-B1 | ANTIDEPRESSANT DERIVATIVES OF TRANS-4-PHENYL-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 1983-03-02 | — | — | EP | claimed |
| EP-0030081-A1 | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof | PFIZER INC. (US) | 1981-06-10 | — | — | EP | claimed |
| US-10266481-B2 | Organocatalytic asymmetric synthesis of antidepressants | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2019-04-23 | — | — | US | disclosed |
| EP-1904066-B1 | COMBINATIONS OF ESZOPICLONE AND TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE, for treating MENOPAUSE, perimenopause AND COGNITIVE DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2018-05-23 | — | — | EP | disclosed |
| US-20170158607-A1 | ORGANOCATALYTIC ASYMMETRIC SYNTHESIS OF ANTIDEPRESSANTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-06-08 | — | — | US | disclosed |
| US-20170158607-A1 | ORGANOCATALYTIC ASYMMETRIC SYNTHESIS OF ANTIDEPRESSANTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-06-08 | — | — | US | disclosed |
| US-20140315910-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | SEPRACOR INC. | 2014-10-23 | — | — | US | disclosed |
| US-20140315910-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | SEPRACOR INC. | 2014-10-23 | — | — | US | disclosed |
| US-20130065904-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065904-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8329950-B2 | Process for preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1Napthalenamine | SUNOVION PHARMACEUTICALS INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20050059654-A1 | Method for treatment of depression and anxiety disorders by combination therapy | ARNERIC STEPHEN P (US) | 2005-03-17 | — | — | US | disclosed |
| US-20030083338-A1 | Compositions and methods for management of serotonin-mediated disorders | SEPRACOR, INC. | 2003-05-01 | — | — | US | disclosed |
| US-6482440-B2 | FLUOXETINE, PAROXETINE, SERTRALINE, NEFAZODONE, VENLAFAXINE, TRAZODONE, BUPROPRION, MIRTAZAPINE, FLUVOXAMINE, DULOXETINE, SALTS AND LONG CHAIN DERIVATIVES OF THOSE COMPOUNDS | PHASE 2 DISCOVERY, INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020132854-A1 | Long acting antidepressant microparticles | PHASE 2 DISCOVERY, INC. | 2002-09-19 | — | — | US | disclosed |
| WO-1999057093-A1 | PROCESS FOR THE PREPARATION OF SERTRALINE AND ITS 1,R-STEREOISOMER | EGIS Gyógyszergyár Rt. (HU) | 1999-11-11 | — | — | WO | disclosed |
| EP-0415612-B1 | Use of sertraline for the treatment of chemical dependencies | PFIZER (US) | 1993-11-10 | — | — | EP | disclosed |
| US-4536518-A | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine | PFIZER INC. (US) | 1985-08-20 | — | — | US | disclosed |
| US-4536518-A | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine | PFIZER INC. (US) | 1985-08-20 | — | — | US | disclosed |
| EP-0030081-B1 | ANTIDEPRESSANT DERIVATIVES OF CIS-4-PHENYL-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 1983-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315910-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | HTR4, HTR2C, HTR1D | SLC6A4 38/4885MEN1 1045/4885KMT2A 365/4885 |
| US-20050059654-A1 | Method for treatment of depression and anxiety disorders by combination therapy | SLC6A2, SLC18A2, ADRA2C | SLC6A4 4/4885MEN1 4090/4885KMT2A 1893/4885 |
| US-10266481-B2 | Organocatalytic asymmetric synthesis of antidepressants | TPH1, NAT1, TPH2 | SLC6A4 14/4885MEN1 1676/4885KMT2A 1181/4885 |
| US-20130065904-A1 | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | HTR4, HTR2C, HTR1D | SLC6A4 38/4885MEN1 1045/4885KMT2A 365/4885 |
| US-20020132854-A1 | Long acting antidepressant microparticles | HTR5A, HTR6, HTR7 | SLC6A4 7/4885MEN1 819/4885KMT2A 3486/4885 |
| US-20170158607-A1 | ORGANOCATALYTIC ASYMMETRIC SYNTHESIS OF ANTIDEPRESSANTS | TPH1, NAT1, TPH2 | SLC6A4 14/4885MEN1 1676/4885KMT2A 1181/4885 |
| US-20030083338-A1 | Compositions and methods for management of serotonin-mediated disorders | HTR5A, TPH1, HTR4 | SLC6A4 12/4885MEN1 4284/4885KMT2A 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.